KRAS and non-small cell lung carcinoma: Finally, a lipid nanoparticle (LNP) encapsulating an siRNA inhibitor of glutathione-s-transferase P (GSTP) was developed for advanced non-small cell lung cancer (NSCLC) treatment, with a particular focus on Kirsten rat sarcoma virus (KRAS) mutant tumors.